Spruce Biosciences, Inc.
SPRB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001683553
No open-market purchases or sales by Spruce Biosciences, Inc. insiders were filed in the last 90 days; 65 institutions reported holding it in 13F filings for Q2 2026, worth $116.3M in total; no superinvestor holds it.
Q1 2026 vs. Q4 2025
How the institutions holding Spruce Biosciences, Inc. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Of which not filed for Q1 2026 | Q1 2026 | Change |
|---|---|---|---|---|
| Holders | 32 | 1 | 32 | +1 |
| Shares | 753.9K | 17.9K | 739.8K | +3.78K (+0.5%) |
| Value | $65.6M | $1.56M | $48.3M | −$15.7M (−24.5%) |
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (10)
Institutions that held Spruce Biosciences, Inc. at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Millennium Management LLC | 111,888 | $7.31M | 0.01% |
| Vanguard Capital Management LLC | 18,337 | $1.20M | 0.00% |
| Diadema Partners LP | 10,000 | $653.5K | 0.27% |
| StemPoint Capital LP | 6,360 | $415.6K | 0.08% |
| Vanguard Fiduciary Trust Co | 5,514 | $360.3K | 0.00% |
| Goldman Sachs Group Inc | 5,506 | $359.8K | 0.00% |
| Persistent Asset Partners Ltd | 2,528 | $165.2K | 0.06% |
| Citigroup Inc | 939 | $61.4K | 0.00% |
| Vanguard Global Advisers, LLC | 452 | $29.5K | 0.00% |
| Cassaday & Co Wealth Management LLC | 2 | $130 | 0.00% |
Sold out (9)
Institutions that held Spruce Biosciences, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Schonfeld Strategic Advisors LLC | 24,767 | $2.16M |
| Caligan Partners LP | 20,514 | $1.79M |
| Stonepine Capital Management, LLC | 19,742 | $1.72M |
| Superstring Capital Management LP | 12,137 | $1.06M |
| SkyView Investment Advisors, LLC | 3,000 | $261.0K |
| Northern Trust Corp | 2,422 | $211.0K |
| BNP Paribas Arbitrage, SA | 2,000 | $174.2K |
| Bank of America Corp | 93 | $8.10K |
| Royal Bank of Canada | 40 | $3.00K |
Not filed for Q1 2026 yet (1)
Institutions that held Spruce Biosciences, Inc. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Vanguard Group Inc | 17,873 | $1.56M |